A phase II baseline versus treatment study to determine the efficacy of raltegravir (ISENTRESS) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2012
This article has no abstract
Epistemonikos ID: be240ea3c0e40a2d5af98fd35ef79ea599fa2a24
First added on: Jan 22, 2025